Intravenous furosemide plus hypertonic saline significantly reduced NT-proBNP (delta 3506 vs 905 pg/mL) compared to furosemide alone in patients with acute decompensated heart failure.
RCT (n=200)
Single-blind
Computer-generated random sequence (1:1)
No
Does intravenous furosemide plus hypertonic saline solution improve inflammatory, remodeling markers, and epigenetic signatures in adults with acute decompensated heart failure?
Adding small-volume hypertonic saline to intravenous furosemide in acute decompensated heart failure favorably modulates inflammatory and remodeling biomarkers as well as epigenetic signatures compared to furosemide alone.
Tasa de eventos absoluta: 3506% vs 905%
valor p: p=<0.0005
Aging | doi:10.18632/aging.206364. Mario Daidone, Alessandra Casuccio, John Sebastian Soldano, Valerio Vassallo, Gaetano Pacinella, Maria Grazia Puleo, Roberta Oliveri, Giuseppe Clemente, Daniela Colomba, Giuseppe Miceli, Vittoriano Della Corte, Rosaria Pecoraro, Tiziana Di Chiara, Domenico Di Raimondo, Carlo Domenico Maida, Sergio Ferrantelli, Antonino Tuttolomondo
Daidone et al. (Thu,) conducted a rct in Acute decompensated heart failure (ADHF) with reduced ejection fraction (HFrEF) (n=200). Intravenous furosemide plus hypertonic saline solution (HSS) vs. Intravenous furosemide alone (120-250 mg twice daily) was evaluated on Reduction in serum levels of heart failure markers (NT-proBNP delta) (p=<0.0005). Intravenous furosemide plus hypertonic saline significantly reduced NT-proBNP (delta 3506 vs 905 pg/mL) compared to furosemide alone in patients with acute decompensated heart failure.